# Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

> **NCT04250350** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 206 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** Lebrikizumab

## Key facts

- **NCT ID:** NCT04250350
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-06-22
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04250350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04250350, "Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04250350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*